Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Other 1

Conditions

Weight Loss 1Sarcopenia 1Postoperative Complications 1Obesity 1Muscle Weakness 1Intermittent Fasting 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 297Fluorouracil 272Bevacizumab 235Gemcitabine 234Leucovorin 212Capecitabine 204pembrolizumab 200Nivolumab 157Irinotecan 156Cisplatin 148Specimen Handling 143Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 115Paclitaxel 109durvalumab 104Cetuximab 102Radiotherapy 96atezolizumab 92Biopsy 92Drug Therapy 91Albumin-Bound Paclitaxel 78tislelizumab 77Taxes 73Folfox protocol 68lenvatinib 67Carboplatin 65regorafenib 60Blood Specimen Collection 60trifluridine tipiracil drug combination 52Ipilimumab 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Caloric Restriction × Gastrointestinal × 1 year × Clear all
NCT05114798 2026-05-22

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

University of Illinois at Chicago

Phase NA Active not recruiting
193 enrolled
GastrointestinalOther

Intermittent Fasting, Obesity, Colorectal Neoplasms, Weight Loss

NCT03676478 2025-12-10

EFECTS

University Hospital, Gasthuisberg

Phase NA Terminated
239 enrolled
Gastrointestinal

Esophageal Neoplasms, Postoperative Complications, Muscle Weakness, Sarcopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡